The prevalence of diabetes mellitus in Asia is rapidly increasing. Diabetes in Asia develops in a shorter time, at a younger age and in individuals with a lower body mass index than in the West. This review summarises the epidemiology and pathophysiology of diabetes in Asia as well as the difficulties and challenges in using HbA1c as a diagnostic test in the region.
by Dr R. C. Hawkins
The worldwide rates of diabetes mellitus have more than doubled in the last 30 years, driven by diet, obesity and lifestyle factors [1]. The International Diabetes Federation predicts that the number of individuals affected by diabetes will increase from 240 million in 2007 to 380 million by 2025 [2]. Diabetes is an important health priority in Asia involving huge individual, societal and national costs. Agreement as to appropriate criteria for diagnosis is essential for patient management as well as healthcare planning and epidemiological discussion.
Epidemiology of diabetes in Asia
Asia is a heterogeneous region in terms of ethnicity, culture and socioeconomic development and great differences are seen in the prevalence of diabetes both between and within Asian countries. As the world’s most populous region, Asia is projected to comprise more than 60% of the global diabetic population by 2025. The effects of high population growth, ageing and increasing urbanisation suggest that India and China will remain the two countries with the highest numbers of people with diabetes (79 million and 42 million, respectively) by 2030 [3]. Other Asian countries (Indonesia, Pakistan, Bangladesh, and the Philippines) are in the top ten countries for diabetes prevalence. The prevalence of impaired glucose tolerance in Southeast Asia was estimated as 6.0% in 2007, suggesting that there is a substantial population pool at risk of developing overt diabetes. Differences between ethnic groups may be seen in a single country. In Singapore, a nationwide study in 1998 showed the prevalence of diabetes to be highest in the Indian population (12.8%) followed by Malays (11.3%) and Chinese (8.4%). Age-specific prevalence also varies between Asian populations, with a peak in Indians at 60-69 years compared to 70-89 years in Chinese. South Indians have a higher age-specific prevalence and prevalence of impaired glucose tolerance at a younger age than Chinese. A particular characteristic of diabetes in Asia is the high prevalence of young-onset diabetes. The prevalence of diabetes in China in the 35-44 year age group rose by 88% between 1994 and 2000 while the fraction of diabetics under 44 years of age rose from 25% to 35.7% in South India between 2000 and 2006. Rates of diabetes in children across the region also show alarming rises.
Pathophysiology of diabetes in Asia
The prevalence of insulin resistance and metabolic syndrome is high in Asian people. Although Asian populations have lower rates of obesity than Western populations as defined by the conventional body mass index cut-offs, the prevalence of diabetes in Asians often matches or exceeds that in the West.
Compared to Europeans, Asians have lower muscle mass and increased abdominal obesity and visceral fat. Obesity is associated with many of the metabolic mechanisms that worsen insulin tolerance. Excess lipolysis leads to elevation of blood non-esterified fatty acids and triglycerides, suppressing glucose uptake by muscle. Obesity can also diminish insulin action through leptin and adiponectin secretion. This difference in body fat varies between Asian ethnicities and explains in part the differences in diabetes prevalence seen between ethnic groups. For example, for the same age and BMI, Singaporean Indians have the greatest percentage of body fat, followed by Malays and then Chinese; an order reflecting the different prevalence of diabetes in each group. All three ethnicities have higher body fat percentages than Europeans. The World Health Organisation convened an expert consultation to review the BMI cut offs to define risks in Asian populations and recommended that for Asians, BMI of 23 kg/m2 or higher marks a moderate increase in risk while a BMI of 27.5 kg/m2 or more represents high risk. Several Asian countries have subsequently adopted lower BMI cut-offs than those used in the West. India and Japan use BMI cut-offs of 23 and 25 to define overweight and obese categories while Singapore uses 23 and 27.5 kg/m2.
Genetic differences in risk allele frequencies and location for diabetes genes between Asian and European populations may contribute to some of the physiological differences observed. Asians, especially from Southeast Asia, show higher postprandial glucose concentrations and lower insulin sensitivity than Europeans following a glucose challenge despite controlling for age, BMI, waist circumference, birth weight and diet. Frequency differences between Asian and European populations include transcription factor 7-like 2 gene TCF7L2 (rs7901349) with a minor allele frequency of 0.03 in Asians and 0.27 in Europeans and the potassium voltage-gated channel, subfamily Q, member 1 gene KCNQ1 (rs2237892) with allele frequency of 0.28-0.41 in East Asians and 0.05-0.07 in Europeans. The effect of the same genetic variant may also vary between populations. For example, the effect of the FTO variant is linked to changes in fat mass and obesity in Europeans but its link to body size is weaker in Indian populations.
Nutritional factors may also play a role in the increased rates of diabetes seen in Asia. Increasing urbanisation across Asia has seen an increase in consumption of animal products and fat. Some traditional food sources such as ghee (clarified butter), which is high in trans fatty acids, and polished rice and refined wheat (which have high glycaemic indices) may contribute to obesity and glucose intolerance. Such dietary factors, coupled with an increasingly sedentary lifestyle (e.g. replacement of bicycles with automobiles across Asia) and high cigarette smoking rates (which increases insulin resistance), are helping fuel diabetes rates across the region.
Diagnosis of diabetes mellitus in Asia
Diabetes mellitus has traditionally been defined as a state of chronic hyperglycaemia and measurement of blood glucose concentrations has been the gold standard criterion for diagnosis. The International Expert Committee recently recommended that diabetes should be diagnosed when HbA1c is ≥6.5% and this approach has been adopted by the American Diabetes Association [4].
HbA1c results from the reaction of glucose with the N-terminal valine of the β chain of haemoglobin to form the aldimide (Schiff base or labile HbA1c), which then undergoes an Amadori rearrangement to the stable ketoamine (HbA1c) [5]. To compensate for variation in the total haemoglobin concentration, HbA1c is expressed as a ratio (HbA1c/total haemoglobin). There are a variety of analytical methods for HbA1c determination, including those based on charge differences (e.g. ion-exchange chromatography, electrophoresis, capillary electrophoresis and isoelectric focusing) and structural differences (e.g. affinity chromatography, immunochemical and enzymatic assays). Methods based on charge differences face potential interferences from other haemoglobin moieties (e.g., Schiff base, carbamylated haemoglobin, and haemoglobin variants). Affinity chromatography measures all glycohaemoglobin bound to the resin, not just HbA1c, and thus results are not specific for HbA1c. However as the ratio of HbA1c to all glycohaemoglobin is fixed, it is possible to standardise the reporting to HbA1c equivalent units. Immunoassays are generally less affected by the structural changes of haemoglobin variants than other methods.
There are more than 700 known haemoglobin variants and about half of these variants are clinically silent. The prevalence and type of haemoglobinopathy in Asia differs from that seen in Western populations. Both α and β haemoglobin chain variants can interfere with HbA1c measurement [6]. Common haemoglobin variants seen in Asia affecting HbA1c measurement include HbE, HbC and HbS. Thalassaemia is also endemic in the region and may be accompanied by an increase in HbF concentration. High proportions of HbF compared to HbA can cause falsely low values for HbA1c when the ratio of HbA1c to total haemoglobin is calculated. Red cell lifespan can also be reduced in thalassaemia, causing falsely low HbA1c values. Since many commercial HbA1c methods have been optimised for Western settings, ensuring accurate measurement in Asian populations can be an analytical challenge for the laboratory.
The suggestion that diabetes should be diagnosed when HbA1c is ≥6.5% has led to increasing study in differences in HbA1c between ethnic groups. HbA1c has been shown to be higher in non-Caucasian populations, including Hispanics, Asians and Africans. In a study of Caucasian, Chinese, Malay, Eurasian and Indian outpatients in Singapore, we have shown that HbA1c in all Asian groups was higher than the Caucasian group when corrected for age, sex and fasting glycaemic concentration [7]. Compared to the Caucasian group, Malays and Indians had the highest HbA1c (both 0.6 %HbA1c units higher), followed by Eurasians and Chinese (both 0.3%). The reasons for these ethnic differences in HbA1c are unclear, with potential mechanisms including biological (e.g. glycation and erythrocyte survival) and social (cultural/economic) factors.
We recently examined the performance of HbA1c compared to oral glucose tolerance testing (OGTT) for the diagnosis of diabetes in our outpatient population. Details of OGTT with paired HbA1c samples from 2005-11 were extracted from the laboratory database for statistical analysis. OGTT (75 glucose) was performed and interpreted according to WHO recommendations with 0 and 120 min sampling. All HbA1c (turbidometric immunoinhibition method) and glucose measurements were performed on Beckman Coulter LX20 PRO analysers. Diabetes mellitus was diagnosed using three different methods: (1) fasting plasma glucose ≥ 7.0 mmol/L, (2) 120 minute post prandial plasma glucose ≥ 11.1 mmol/L and (3) fasting plasma glucose ≥ 7.0 mmol/L or 120 minute post prandial plasma glucose ≥ 11.1 mmol/L.
There were 212 records available with average age 57y (29-95); 134 men, 168 Chinese, 28 Indian, 16 Malay. The prevalence of diabetes by (1) was 25%, by (2) was 43%, by (3) was 48% and using a HbA1c cut-off of 6.5% was 38%. The AUC for HbA1c to predict diabetes [see Figure 1] by (1) was 0.89 (95% CI: 0.83-0.94), by (2) was 0.74 (0.67-0.81) and by (3) was 0.78 (0.72-0.85). At the suggested cut-off of HbA1c 6.5% [see Table 1], concordance, kappa and phi values between diabetes diagnosis by HbA1c and (1) was 78%, 0.54, 0.64; (2) 72%, 0.43, 0.44; and (3) 74%, 0.48, 0.50. Maximum efficiency for HbA1c in detecting diabetes as defined by (3) was 0.75 at a cut-off of 6.2% (sensitivity 0.804 (0.714-0.876), specificity 0.691 (0.596-0.776)). There was no significant difference in the age, sex or ethnic makeup of the diabetic groups identified by HbA1c testing or by the other three criteria. Thus there was significant discordance of diabetic classification between use of HbA1c and the OGTT results with a 10% absolute reduction in diabetes prevalence with use of a HbA1c cut-off of 6.5% alone. Thirty-seven percent of OGTT-positive individuals would not be identified by a HbA1c cut-off of 6.5% while 15% of OGTT-negative individuals would be identified as diabetic. These results suggest that the two approaches are not interchangeable and appear to identify different patient groups.
This small study supports reports from large epidemiological studies of lack of agreement between HbA1c- and glucose-based diagnosis and lower prevalence rates with the HbA1c-based criterion [8-10]. Moving to HbA1c-based diagnosis of diabetes can be anticipated to have a substantial effect on prevalence rates and will identify different individuals from the traditional glucose-based criteria. Given that the epidemiology and pathophysiology of diabetes in Asia differs from Western populations, it is perhaps not surprising if diagnostic criteria may need to be customised to local conditions. The need or desirability for different ethnic-based HbA1c cut-offs is unclear and further work is required to examine HbA1c in different ethnic groups within Asia. As HbA1c and glucose-based criteria appear to identify different groups, a clear algorithm outlining the order of testing is required to clarify the role of HbA1c and glucose-based criteria. Unstandardised use of HbA1c and glucose diagnostic testing will complicate epidemiological study of diabetes, both within and between countries. Although a routine combined approach using both HbA1c and glucose measurements may allow the greatest detection of diabetics, it may not be practical or economically feasible for many in Asia. These problems illustrate the difficulty in global standardisation of disease definitions using biological markers and the need to validate approaches in local ethnic populations before introduction.
References
1. Danaei G et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants. Lancet 2011;378:40
2. Chan JC et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
3. Ramachandran A et al. Diabetes in Asia. Lancet 2010;375:408-18
4. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
5. Weykamp C et al. A review of the challenge in measuring hemoglobin A1c. J Diabetes Sci Technol 2009;3:439-45
6. Schnedl WJ et al. Hemoglobin variants and determination of glycated hemoglobin (HbA1c). Diabetes Metab Res Rev 2001;17:94-8
7. Hawkins R. Differences in HbA1c between Caucasians, Chinese, Indians, Malays and Eurasians. Clin Chim Acta 2011;412:1167
8. Malkani S et al. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 2011;124:395-401
9. Kim CH et al. Discordance between fasting glucose-based and hemoglobin A1c-based diagnosis of diabetes mellitus in Koreans. Diabetes Res Clin Pract 2011;91:e8-e10
10. Christensen DL et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580-2
The author
Dr Robert C Hawkins
Department of Laboratory Medicine
Tan Tock Seng Hospital
Singapore
e-mail: Robert_Hawkins@ttsh.com.sg
Mild hypothyroidism describes the condition where the plasma levels of thyroid stimulating hormone (TSH) are above the ‘normal’ upper limit (which is still a subject of debate) but where there is no equivalent change in circulating levels of the thyroid hormones tetraiodothyronine (T4) and triiodothyronine (T3). Many studies have concluded that since the majority of patients suffering from mild hypothyroidism have few signs and symptoms of thyroid dysfunction and that eventual overt disease is not inevitable, screening is not cost-effective except during pregnancy or in cases where there is a family history of thyroid disease or prior thyroid dysfunction. However there are two groups of people, namely menopausal women and subjects with Down syndrome (DS), who are particularly at risk and who may have difficulty recognising symptoms of overt disease should they occur. Might it not be prudent to screen these high-prevalence populations on a regular basis?
Various studies have shown that by the age of 50 around 10% of women have some symptoms of hypothyroidism, and by the age of 65 the prevalence in women is in the range of 15-20%. Not only is hypothyroidism an insidious condition, but several of the symptoms are also commonly associated with the menopause, including fatigue, sleep disturbances, weight gain, mild cognitive impairment and depression. It is thus likely that many older women with thyroid dysfunction do not seek help, and several studies have shown that many remain undiagnosed even if such help is sought. Indeed a survey by the American Association of Clinical Endocrinologists found that only a quarter of women who had discussed their menopausal sysmptoms with a physician were tested for thyroid function, though it is know that these symptoms are greatly alleviated when euthyroidism is maintained.
While routine screening detects the increased prevalence of congenital hypothyroidism in neonates with DS, thyroid dysfunction presenting later affects around five percent of DS children and over ten percent of adults. Clinical diagnosis in this group is problematic, since the DS phenotype can mask clinical features of thyroid disease, and such symptoms may also be attributed to the syndrome itself. In addition some patients may not be able to articulate their symptoms effectively.
So surely the regular screening of older women and subjects with Down syndrome is warranted to ensure that overt thyroid disease is avoided or treated promptly should it occur.
Plague is an acute bacterial infection in man caused by Yersinia pestis. Historically, it has resulted in devastating pandemics (Black Death) throughout the world with high mortality rates in which pneumonic man-to-man transmission followed the usual flea-to-man transmission [1]. Plague may have retreated over the past decades due to availability of effective antibiotics and intensive vector control, but it has not been completely eradicated [2], and the third pandemic can be regarded as still ongoing, since Y. pestis sporadically re-emerges from its reservoir of wild rodents and spreads to the human population [3]. During the last 15 years more than 20 countries have reported plague cases to the WHO [3].
Outbreaks of plague in India emphasise the need to maintain the necessary skills and public health infrastructure to detect, monitor and combat a wide range of in infectious disease agents. Y. pestis is spread by aerosol and is usually fatal if treatment is not started within 24 hours of onset of symptoms [3,4]. A precise and quick diagnosis of plague allows prompt intervention, especially necessary during plague outbreaks. When rapidly diagnosed and promptly treated, plague may be successfully managed with antibiotics, reducing the mortality from 60% to less than 15% [5,6].
Clinical features
The diagnosis of plague still relies on clinical symptoms and exposure history in most endemic areas [1,3]. The three main clinical presentations of plague are bubonic, septicaemic and pneumonic plague. Bubonic plague is the classical form of the disease, characterised by fever, headache, chills and swollen, extremely tender lymph nodes or buboes within 2-6 days after contact with the pathogen. Buboes typically involve lymph nodes that drain the site of initial infection and are usually located in the inguinal, axillary or cervical region. In septicaemic plague, patients have positive blood cultures without palpable lymphadenopathy. Clinical symptoms, such as chills, headache, malaise and gastrointestinal disturbances resemble septicaemia caused by other gram negative bacteria. Pneumonic plague is the rarest form of plague with the highest mortality rate. Signs of pneumonic plague include severe pneumonia accompanied by high fever, dyspnea and often haemoptysis.
Laboratory diagnosis
Laboratory diagnosis of plague is mainly based on bacteriological and/or serological evidence. However molecular biological techniques based on PCR and DNA hybridisation have also been developed in recent years. Plague should be suspected if: clinical symptoms are compatible with plague i. e., fever and lymphadenopathy in a person who resides in or has recently travelled to a plague-endemic area; and small gram-negative and/or bipolar-staining coccobacilli are seen on a smear taken from affected tissues, e.g. bubo (bubonic plague), blood (septicaemic plague) and tracheal/lung aspirate (pneumonic plague).
The presumptive diagnosis of plague can be made if: an immunofluorescence stain of a relevant sample is positive for the presence of Y. pestis Fraction 1 capsular (F1) antigen; and a single serum specimen is tested and the anti-F1 antigen titre by agglutination is >1:10.* Confirmed plague is diagnosed if: an isolated culture is lysed by specific bacteriophage; two serum specimens demonstrate a four fold anti-F1 antigen titre rise by agglutination testing;* and a single serum specimen tested by agglutination has a titre of >1:128 and the patient has no known previous plague exposure or vaccination history.*
*Agglutination testing must be shown to be specific to Y. pestis F1 antigen by
haemagglutination inhibition.
Bacteriological work-up
This includes microscopy, isolation by cultivation, identification and confirmation by NAT tests and animal pathogenicity tests for Y. pestis. Specimens should be obtained from relevant sites at the appropriate time to enhance the reliability of the results. The preferred specimen for microscopic examination and isolation from a bubonic case is pus from an accessible bubo, which contains numerous organisms. Blood cultures should be taken whenever possible, particularly in septicaemic plague. Bronchial/tracheal washing should be taken from patients suspected of pneumonic plague. Throat swabs are not ideal for isolation of plague bacilli since they often contain many other bacteria that can mask the
presence of plague organisms [9].
Staining techniques such as Gram, Giemsa, Wright or Wayson stains can provide supportive but not confirmatory evidence of plague [2]. Blood smears taken from suspected bubonic plague patients are frequently negative as the bacteria are intermittently released from lymph nodes; periodic specimen collection at 10-30 minutes intervals gives more reliable results [9]. Sputum or throat smears taken from pneumonic plague patients may contain too many other organisms which can mask plague if only the staining techniques mentioned above are used. In addition smears should be stained using the more specific fluorescent antibody test (FA), which utilises fluorescent dye and targets capsular F1 antigen expressed predominantly at 37° C [2,9]. A positive fluorescent antibody test can be used as presumptive evidence of Y. pestis infection however it necessitates a specialised instrument along with costly reagents. Samples that have been refrigerated for more than 30 hours or collected from cultures that were incubated at temperatures lower than 35°C (from fleas, for instance) may be negative [2].
Specimens intended for culture should be taken before antibiotic therapy is started [2]. Y. pestis takes two days to form visible, hammered metal-like colonies. If patients have been treated with a bacteriostatic antibiotic for more than four days, bacterial cultures should be incubated for more than five days to allow the remaining organisms to build up a population. A single colony from the culture is then tested for Y. pestis using biochemical tests, inoculation into laboratory animals and use of specific bacteriophage. All automated microbiological test systems are not programmed to identify Y. pestis and its low growth rate restricts the use of biochemical identification [2]. Lysis by specific bacteriophage is used by the CDC to conclusively identify Y. pestis [2], but all these procedures are too complex and time-consuming, and also expensive. Furthermore, incorrect handling while shipping the specimens from the collection centre to the diagnostic centres may lead to desiccation, contamination of the samples and consequent death of the bacteria [6].
Serological analysis
Serological tests are useful especially when cultures yield negative results [9] and/or only serum samples are available as clinical specimens. Such tests are often used retrospectively to confirm the diagnosis of plague; paired serum samples are collected during either the acute and convalescent phases or the convalescent and post-convalescent phases. Serological tests are primarily based on Passive Haemagglutination (PHA) tests and ELISA [10]. PHA has been routinely performed for the last 30 years for the serodiagnosis of plague according to the procedure described by the WHO (1970), which advocates the use of formaldehyde-fixed and F1 sensitised sheep RBC. Being a simple, cheap, rapid and sensitive method, it is regularly practiced at CDC to analyse samples for the presence of anti-F1 antibodies. A four-fold rise in the titre is considered confirmatory for plague. A single serum sample with a titre greater than 1:10 in a person not previously infected or vaccinated against plague is presumptive evidence of recent infection [2]. However, PHA has proved to be an invaluable tool in surveillance programmes for large scale screening [11].
Using monoclonal antibody as a capture antibody and purified rabbit immunoglobulin as an indicator, Williams et al described an ELISA that detects up to 8 ng of F1 antigen per mL serum [12]. ELISA has been used to measure the level of F1 antigen as well as IgG and IgM antibodies to F1 antigen. Detection of IgM antibodies by ELISA in convalescent phase sera is indicative of recent infection. However because of the low concentration of IgM antibody relative to IgG, it is conceivable that some early convalescent phase sera may be IgG positive but IgM negative [12]. Even though it is efficient for serodiagnosis, plague ELISA is not widely accepted because it is less sensitive than FA [12], difficult to perform in the field, and requires specific equipment and expensive reagents.
As well as the two tests described above, tests such as complement fixation and immunodiffusion tests have also been used for plague diagnosis, but have not been widely accepted due to their long turn around time and greater complexity [12]. Furthermore the rarely encountered cases with weak F1 antigen expression also limit the sensitivity of serodiagnostic tests for plague. The latest developments in immunological test design have resulted in availability of rapid diagnostic tests (RDT for plague diagnosis, discussed later in this article.
Nucleic acid tests
When live organisms are not available, e.g., in specimens taken postmortem from lymphoid tissues, lung and bone marrow, DNA of Y. pestis can still be detected [2, 9, 10]. Such methods include PCR and DNA hybridisation techniques. PCR, utilising primers derived from the pla and caf 1 genes that are contained in two different Y. pestis virulence plasmids, can detect levels as low as 10-50 bacteria and thereby help in presumptive diagnosis of plague [10]. However the sensitivity of the method was found to be low when it was used in a field study [13]. This may have been due to suboptimal field conditions and the small volumes of samples used for DNA extraction [13]. Several methods for amplification of Y. pestis DNA have been developed, but none of them has been evaluated with clinical specimens. In spite of its probable usefulness in field studies, DNA hybridisation techniques are of minimal value due to their low limit of detection (minimum of 105 bacteria) and the longer time required to perform the tests [2].
Rapid tests
Even though a number of presumptive and confirmative techniques are available, none are sufficiently simple, economical and non-instrumental to be used routinely by clinical laboratories and in field studies, surveillance or point-of-care testing [2]. The RDT for plague based on F1 antigen has been tested in laboratories and has provided promising results. It is as specific as and at least as sensitive as the available standard methods for plague diagnosis. The excellent specificity of RDT coupled with its lower detection threshold makes it a very useful screening test, in addition to bacteriological tests and ELISA [4].
Span’s Crystal Ypes is a simple and cost-effective RDT based on the principle of immunochromatography. As in the company’s other immunochromatography tests, monoclonal antibodies labelled with a visually detectable marker viz. colloid gold bind to the target antigen. The complex is arrested at the test area (band) coated with another monoclonal antibody and forms a visible band. To the best of our knowledge, it is the only commercially available RDT to diagnose plague at present. The test detects the F1 antigen specific for Y. pestis, which is present in large amount in sputum and bubo samples of infected people. The F1 antigen is stable in tropical climates and can be still be detected in patients after several days of treatment [4]. F1 antigen is detected at a wider range of concentration than other tests, within 10-15 minutes, without the prozone phenomenon, thus avoiding false negative results especially in post mortem specimens or sputum specimens which can contain a very high concentration of F1 antigen [4]. The striking feature of Crystal Ypes is the innovative design of its sample processing device, which minimises the laboratory operator’s contact with highly contagious clinical specimens such as bubo aspirates and tracheal wash without compromising the ease and simplicity of carrying out the test. Because the F1 antigen is highly stable, and there is a reasonably good detection threshold, a short time to result and the test is cost-effective, it is the most suitable test for the immunodetection of plague even in anthropological applications such as burial site studies, especially when archeological and historical data are incomplete or non-existent [14,15].
References
1. Butler T et al. Journal of infectious disease 1977; 136(2): 317-320.
2. Perry RD and. Fetherston JD. Clinical Microbiology reviews 1997; 10(1): 35-66.
3. Thullier P et al. Am J Med Hyg 2003; 69(4): 450-451.
4. Chanteau S et al. The lancet 2003; 361: 211-216.
5. WHO programmes and projects global alert and response, disease covered by EPR, Plague, 2009.
6. Leal NC, de Almedia MP. Rev Med trop S Paulo 1999; 41(6):339-342.
7. Infectious disease epidemiology section office of Public health, Louisiana Dept of Health and hospitals, plague, 2004.
8. CDC report, Division of vector born disease, Plague, Laboratory test criteria for diagnosis of plague, 2005.
9. CDC, Plague diagnosis CDC Division of vector born infectious diseases, 2005.
10. Murry PR et al. Manual of Clinical Microbiology, 8th Ed. ASM press, 2003, 673-683.
11. de Almeida AMP and de Souza FLC. Mem Inst Inst Oswaldo Cru [online]. 1992; 87 n.1 ISSN 0074-0276. [Online]. 1992; 87 no.1 ISSN 0074-0276
12. Shepherd AJ et al. Journal of Clinical Microbiology 1986; 24(6):1075-1078.
13. Rahalison L et al. Institut Pasteur de Madagascar, Antananarivo, Madagascar 1999.
14. Bianucci R et al. American Journal of Physical Anthropology 2008; 136(3):361-7
15. Bianucci R et al. C R biologies 2007; 33: 0747-754.
Span Diagnostics Ltd
Udhna, Surat, India
AB SCIEX achieves ISO 13485 certification for manufacturing of LC/MS systems, and opens Asia Pacific Application & Training Centre in Singapore’s biomedical hub
AB SCIEX, a global leader in life science analytical technologies, today announced that it has achieved ISO 13485 certification for its quality management system. This certifies an international standard that requires a manufacturer to demonstrate a comprehensive and compliant quality management system suitable for the design and manufacturing of medical devices. Such certification is often considered a first step toward complying with European regulatory requirements for a device to be cleared for use in the clinic. AB SCIEX currently manufactures and sells LC/MS/MS systems for research use only.
‘AB SCIEX is taking the necessary steps to be compliant with regulatory requirements that govern entry into clinical diagnostics,’ said Rainer Blair, President of AB SCIEX. ‘Achieving the ISO 13485 certification is an important measure toward realising the vision of our LC/MS/MS systems to be cleared for use in clinics. The potential impact of mass spectrometry technologies on clinical diagnostics is significant.’
The ISO 13485 certification covers AB SCIEX’s manufacturing facility in Singapore as well as its R&D design center in Toronto, Canada. AB SCIEX is a leader with more than 20 years of innovation and market leadership. Its instrumentation is used in clinical research, forensic toxicology, biomedical research and drug discovery and development. The achievement of ISO certification offers customers and suppliers an additional level of confidence in the quality and reliability of AB SCIEX instruments as well as the company’s commitment to continuous improvement.
AB SCIEX has also announced the opening of its newest APAC Regional Application & Training Centre. Located in Singapore’s biomedical hub at Biopolis, this centre provides comprehensive service, support and application development to enable the scientific community in Singapore and the rest of ASEAN, Australia New Zealand, Japan and Korea to continue its increasing use of mass spectrometry technologies for a broad range of applications. The new Singapore facility complements the regional application support centre that the company opened last year in Shanghai, China.
This Singapore facility serves as a regional hub for the scientific community to learn about the latest innovations in analytical-based laboratory instrumentation. Its primary functions include sample analysis, instrument and workflow demonstrations, comprehensive training programs, region-specific applications development, on-site and remote customer support, and scientific collaborations with research leaders in a variety of life science disciplines. The company has a long history of partnership throughout the life science industry within Singapore and across the Asia Pacific region. It serves a broad range of customers in government agencies, academic research, clinical research and pharmaceutical industries.
‘Leading companies such as AB SCIEX continue to play an important role in the development of Singapore’s biomedical sciences sector by providing the latest tools to advance our efforts in drug discovery research. This new centre is an excellent example of how companies can foster synergies and partnerships with the research community in Biopolis to develop innovative and region-specific solutions for Asia,’ said Mr. Kevin Lai, Deputy Director, Biomedical Sciences, Singapore Economic Development Board.’
‘AB SCIEX continues to be a trusted partner for our customers and collaborators in Singapore and throughout the Asia Pacific region,’ said Johnson Ho, Vice President of Sales, Asia-Pacific. ‘Our new APAC Regional Application & Training Centre represents our commitment to deliver world-class service and support to help our customers address critical issues, such as food safety, environmental contamination and the accuracy of clinical research results.’
AB SCIEX www.absciex.com
February | March 2025
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.